Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 5, 2013, Pages 505-508

  Vinikoor, Michael J ^a   Cope, Anna ^a   Gay, Cynthia L ^a   Ferrari, Guido ^b   McGee, Kara S ^b   Kuruc, Joann D ^a   Lennox, Jeffrey L ^c   Margolis, David M ^a   Hicks, Charles B ^b   Eron, Joseph J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute HIV infection; Antiretroviral therapy; Immune activation; NNRTIs; Viral dynamics

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; DIDANOSINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; HLA DR ANTIGEN; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOPATHOLOGY; MALE; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; SEROLOGY; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 84876409568     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318285cd33     Document Type: Article

References (24)

1. Cohen MS, Shaw GM, McMichael AJ, et al. Acute HIV-1 infection. N Engl J Med. 2011;364:1943-1954.
2. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83:3719-3733.
3. Gay C, Dibben O, Anderson JA, et al. Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One. 2011;6:e19617.
4. Deeks SG, Kitchen CMR, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942-947.
5. Fahey JL, Taylor JMG, Manna B, et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS. 1998;12:1581-1590.
6. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543.
7. Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis. 2009;48:350-361.
8. Gay CL, Mayo AJ, Mfalila CK, et al. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS. 2011;25:941-949.
9. Bell SK, Little SJ, Rosenberg ES. Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis. 2010;202:S278-S288.
10. O'Brien M, Markowitz M. Should we treat acute HIV infection? Curr HIV/AIDS Rep. 2012;9:101-110.
11. Fidler S, Fox J, Touloumi G, et al. Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. AIDS. 2007;21:1283-1291.
12. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 2006;194:725-733.
13. Von Wyl V, Gianella S, Fischer M, et al. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One. 2011;6:e27463.
14. McKellar MS, Cope AB, Gay CL, et al. Acute HIV infection in the southeastern United States: a cohort study. AIDS Res Hum Retroviruses. 2013;29:121-128.
15. Linback S, Thorstensson R, Karlsson AC, et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. AIDS. 2000;14:2333-2339.
16. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci. 2012;109:9523-9528.
17. Hunt PW. Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep. 2007;4:42-47.
18. Volberding P, Demeter L, Bosch RJ, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS. 2009;23:1987-1995.
19. Jain V, Hartogensis W, Bacchetti P, et al. ART initiation during acute/early HIV infection compared to later ART initiation is associated with improved immunologic and virologic parameters during suppressive ART [abstract #517]. Paper presented at: 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, MA.
20. Estes J, Baker JV, Brenchley JM, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis. 2008;198:456-464.
21. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199:1177-1185.
22. Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 2006;3:e484.
23. Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One. 2009;4:e7658.
24. Hunt PW, Rodriguez B, Shive C, et al. Gut epithelial barrier dysfunction, inflammation, and coagulation predict higher mortality during treated HIV/AIDS [abstract #278]. Paper presented at: 19th Conference on Retroviruses and Opportunistic Infections; 2012; Seattle, WA.